Brief: Bone Therapeutics Announces 2019 Business Outlook

Biosenic SA

22/01/2019 06:05

Jan 22 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS ANNOUNCES 2019 BUSINESS OUTLOOK AND
REPORTS YEAR-END 2018 CASH POSITION
    * CTA SUBMISSION PLANNED IN H2 2019 TO START DELAYED-UNION
FRACTURES STUDY WITH ALLOB
    * CASH BURN FOR THE FULL YEAR 2018 BELOW GUIDANCE
    * PHASE IIA RESULTS WITH ALLOB IN PATIENTS UNDERGOING A
SPINAL
FUSION PROCEDURE EXPECTED MID-2019
    * CTA SUBMISSION PLANNED IN H2 2019 TO START DELAYED-UNION
FRACTURES STUDY WITH ALLOB
    * COMPANY EXPECTS TO SUBMIT A CTA WITH REGULATORY
AUTHORITIES AND
TO START PHASE III PROGRAMME WITH ENHANCED VISCOSUPPLEMENT
JTA-004
    * PHASE III STUDY WITH JTA-004 IN PATIENTS WITH KNEE
OSTEOARTHRITIS EXPECTED TO START IN H2 2019
    * CASH UTILIZATION OF EUR 13.9 MILLION FOR FULL YEAR 2018
WHICH
WAS BELOW COMPANY'S GUIDANCE
    * IN H2 2019, COMPANY PLANS TO SUBMIT A CLINICAL TRIAL
APPLICATION
(CTA) WITH REGULATORY AUTHORITIES IN EUROPE TO ALLOW START OF A
STUDY WITH ALLOB IN PATIENTS WITH DELAYED-UNION FRACTURES
    * NET CASH POSITION TOTALLED EUR 8.2 MILLION FOR YEAR ENDED
DECEMBER 31, 2018
    * COMPANY ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT
ITS
BUSINESS OBJECTIVES INTO Q4 2019

Source text for Eikon:  ID:nGNE17RH4k 
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))